TY  - JOUR 
AU  - Sobas, Marta Anna
AU  - Turki, Amin T
AU  - Ramiro, Angela Villaverde
AU  - Hernández Sánchez, Alberto
AU  - Elicegui, Javier Martinez
AU  - González, Teresa
AU  - Melchor, Raúl Azibeiro
AU  - Abáigar, María
AU  - Tur, Laura
AU  - Dall'Olio, Daniele
AU  - Sträng, Eric
AU  - Tettero, Jesse M
AU  - Castellani, Gastone
AU  - Benner, Axel
AU  - Döhner, Konstanze
AU  - Thiede, Christian
AU  - Metzeler, Klaus H
AU  - Haferlach, Torsten
AU  - Damm, Frederik
AU  - Ayala, Rosa
AU  - Martínez-López, Joaquín
AU  - Mills, Ken I
AU  - Sierra, Jorge
AU  - Lehmann, Sören
AU  - Porta, Matteo G Della
AU  - Mayer, Jiri
AU  - Reinhardt, Dirk
AU  - Medina, Rubén Villoria
AU  - Schulze-Rath, Renate
AU  - Barbus, Martje
AU  - Hernández Rivas, Jesús María
AU  - Huntly, Brian J P
AU  - Ossenkoppele, Gert
AU  - Döhner, Hartmut
AU  - Bullinger, Lars
PY  - 2025
UR  - http://hdl.handle.net/10366/172086
AB  - [EN]Since 2017, targeted therapies combined with conventional intensive chemotherapy have started to improve outcomes of patients with acute myeloid leukemia (AML). However, even before these innovations, outcomes with intensive chemotherapy had...
LA  - eng
KW  - Leukemia, Myeloid, Acute
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Humans
KW  - Middle Aged
KW  - Male
KW  - Female
KW  - Aged
KW  - Adult
KW  - Treatment Outcome
KW  - Hematopoietic Stem Cell Transplantation
KW  - Young Adult
KW  - Adolescent
KW  - Europe
KW  - Aged, 80 and over
KW  - Prognosis
KW  - Prognosis
KW  - Aged
KW  - Young Adult
KW  - Leukemia
KW  - Hematopoietic Stem Cell Transplantation
KW  - Adult
KW  - Treatment Outcome
KW  - Humans
KW  - Adolescent
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Middle Aged
TI  - Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance
DO  - 10.3324/haematol.2024.285805
T2  - Haematologica
VL  - 110
M2  - 1126
ER  -